March 19 Titan Pharmaceuticals Inc's
experimental drug to treat opioid addiction was shown to be more
effective than placebo in a clinical trial, but the results were
not as strong as might be hoped, reviewers for the U.S. Food and
Drug Administration said in documents published on Tuesday.
The reviewers' commentary was published on the FDA's website
ahead of an advisory panel meeting to be held on Thursday. The
reviewers said results of the trial prompt speculation that
Titan's drug needs to be given at a higher dose and they asked
the panel to advise on whether the company should explore dosing
further before the product is approved.